- Home
- HRMY vs MBIN Comparison
HRMY vs MBIN Comparison
Compare HRMY & MBIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HRMY | MBIN |
|---|---|---|
| Founded | 2017 | 1990 |
| Country | United States | United States |
| Employees | N/A | 735 |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.3B |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | HRMY | MBIN |
|---|---|---|
| Price | $37.03 | $47.80 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 3 |
| Target Price | ★ $44.11 | $43.67 |
| AVG Volume (30 Days) | ★ 854.1K | 184.9K |
| Earning Date | 05-07-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 0.89% |
| EPS Growth | ★ 7.97 | N/A |
| EPS | ★ 0.55 | N/A |
| Revenue | ★ $868,453,000.00 | N/A |
| Revenue This Year | $19.75 | $31.76 |
| Revenue Next Year | $12.88 | $3.73 |
| P/E Ratio | $67.75 | ★ $12.29 |
| Revenue Growth | ★ 21.51 | N/A |
| 52 Week Low | $25.52 | $28.75 |
| 52 Week High | $40.87 | $51.47 |
Technical Indicators
Market Signals| Indicator | HRMY | MBIN |
|---|---|---|
| Relative Strength Index (RSI) | 68.61 | 43.14 |
| Support Level | $35.05 | $44.97 |
| Resistance Level | $39.12 | $48.50 |
| Average True Range (ATR) | 1.04 | 1.46 |
| MACD | 0.22 | -0.25 |
| Stochastic Oscillator | 93.53 | 2.85 |
Price Performance
Historical ComparisonAbout HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About MBIN Merchants Bancorp
Merchants Bancorp is a United States-based bank holding company operating multiple lines of business focused on FHA multi-family housing and healthcare facility financing and servicing, retail and correspondent residential mortgage banking, and traditional community banking. Its segments include Multi-family Mortgage Banking, which originates and services government-sponsored mortgages for multi-family and healthcare facilities; Mortgage Warehousing, which offers mortgage warehouse financing, commercial loans and deposit services; and the Banking segment, which generates maximum revenue and provides portfolio lending for multi-family and healthcare facility loans, residential mortgage banking, agricultural lending, SBA lending and community banking.